In summary, our study identifies sustained increase in circulating HLA-DR+ ILC1s in women with a history of GDM and insulin treatment during pregnancy as compared to GDM patients without insulin treatment and healthy controls, although these immune alterations were likely driven more by overweight/obesity and metabolic changes than by GDM itself. The gene discussed is INS; the disease is gestational diabetes.